ArticleFrontiers in psychiatry2025
Study on the clinical efficacy of repetitive transcranial magnetic stimulation in adolescent patients with depression and its influence on neurotransmitters based on functional near-infrared spectroscopy.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the clinical efficacy of rTMS on adolescent patients with depression and its impact on neurotransmitter levels using fNIRS technology. Methods: Eighty adolescents with major depressive disorder who attended the Psychosomatic Medicine Outpatient Clinic of the Affiliated Hospital of Southwest Medical University between August 2024 and January 2025 were enrolled and randomly assigned to control (n = 40; sertraline hydrochloride + sham rTMS) or research (n = 40; sertraline hydrochloride + active rTMS) groups. All participants received 4 weeks of treatment. Depression severity (HAMD), anxiety severity (HAMA), quality of life (GQOLI-74), cognitive performance (DSST, DST, SVF), fNIRS-derived cortical metrics (frontal and bilateral temporal integral and centroid values), and serum neurotransmitter levels (DA, 5-HT, NE) were assessed at baseline, week 2, and week 4. Results: Baseline characteristics were comparable ( Conclusion: rTMS significantly alleviates depression and anxiety, enhances quality of life and cognitive performance, boosts frontotemporal activity, and increases monoamine neurotransmitter levels in adolescents with major depressive disorder, warranting wider clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.